INTUITIVE Q3 2026 Earnings Release - INTUITIVE SURGICAL INC

Explicit Guidance:

• FY2026 da Vinci Procedures: Narrowed forecast to 14%–15% full-year growth, expecting results to be closer to the midpoint (previously 13.5%–15.5%); range accounts for ACA premium subsidy changes, tender volumes, and competitive intensity in China.
• FY2026 Gross Margin: Non-GAAP gross profit margin forecast revised to 68.3%–68.7% of revenue (previously 68%–69%); includes estimated 90 basis points impact from tariffs and refunds; adjusted for faster growth in newer products (offset) and higher input costs for freight/semiconductor memory.
• FY2026 Operating Expenses: Non-GAAP operating expense growth expected at 11%–13%; no contribution expected to the Intuitive Foundation in 2026 (unlike the $70M contribution in Q4 2025).
• FY2026 Stock Compensation: Non-cash expense estimated between $860 million and $870 million.
• FY2026 Other Income: Non-GAAP other income (mostly interest) forecast between $300 million and $310 million, reflecting lower cash balances post-share repurchases.
• Q4 2026 Tax Rate: Non-GAAP effective tax rate expected to be 22% ± 50 basis points.
• Long-Term Soft Tissue Surgery: Planned update to long-term opportunity estimate for soft tissue surgery in January 2027.
• FY2027 Instrument Pricing: Extended use program (EUP) expansion and volume-based pricing for core wrist instruments on 4th/5th gen platforms to begin rollout in H1 2027; China price reduction taking effect Q4 2026.

Business-Segment Outlook:

• da Vinci Procedures (US & International): U.S. growth driven by benign general surgery, ASC adoption (XIR), and Cardiac/Breast early adoption; International growth led by benign procedures (hysterectomy, cholecystectomy, hernia), with strong expansion in Europe (Germany, UK, Italy) and Asia (India, Japan); China operating environment described as challenging with lower recent capital placements.
• da Vinci 5 & SinglePort (SP): Da Vinci 5 accounted for >25% of U.S. procedures in Q3; SP procedures grew 55% globally (50% US, 40% Korea); U.S. SP vessel sealer submission planned for Q4 2026 to enable wider adoption.
• ION Platform: Reimbursement received in Korea; expect further reimbursement actions in other geographies in coming quarters; Cardiac procedures (300k–400k annual line-of-sight) and Breast surgery (42% growth) identified as early-stage future growth drivers.
• Next-Gen Flexible Robotic Endoscope: FDA 510(k) clearance received in August for non-commercial system for GI tract; program is early in development.
• Telesurgery: Expect several regulatory clearances in the first half of 2028; current telepresence adoption serves as foundation.
• AI Capabilities: Development ongoing for voice-activated UI, automated fourth-arm control, and AI-controlled motion/surgery; deployment at scale deferred pending regulatory/surgeon confidence.
• Capital Placements: 2027 planned expansion into additional countries; 18 systems installed at U.S. ASCs in Q3 with pipeline continuing to build.
• Manufacturing: New INA manufacturing facility in Penang, Malaysia announced; expected to begin operations in 2028.

Market and Competitive Outlook:

• Pricing Strategy: Implemented price reductions for high-volume benign procedures in H1 2027 to expand addressable opportunity; China-specific policy-driven price reduction taking effect November 2026.
• Competitive Dynamics: Intuitive maintains focus on ecosystem, training, and cart-based architecture over modular competitors; belief that modular architecture is not required to serve ASC/benign needs; confidence in elasticity of demand following price reductions.
• Market Expansion: Accelerating entry into new geographies in 2027 (e.g., expanding beyond current footprint); focus on building market access via regulatory clearance, reimbursement, and economic validation country-by-country.

Macro / Industry Outlook:

• U.S. Regulatory/Policy: Monitoring impacts of lower ACA enrollment, Medicaid eligibility changes, and potential 340B policy changes on procedure volumes.
• Global Reimbursement: Ongoing regulatory and reimbursement work in Europe, Asia, and Rest of World to support benign procedure adoption.
• Tariffs: FY2026 guidance includes an estimated 90 basis points impact from tariffs and related refunds; actual impact varies by product/geo mix.

Strategic Initiatives:

• Instrument Extended Use Program (EUP): Expansion of EUP (4th/5th gen) starting H1 2027 to extend instrument life and lower cost-per-procedure; U.S. 510(k) submission in process.
• Litigation Settlement: Reached agreement with U.S. customers regarding third-party remanufacturing/servicing; settlement provides certainty, subject to court approval (expected decision next year).
• R&D Investment: Prioritizing incremental investment in existing platforms and AI; R&D growth rate expected to continue exceeding SG&A.
• M&A/Partnerships: None explicitly announced; focus on organic innovation and ecosystem expansion.

Risks and Headwinds to Outlook:

• Implementation Timing: Pricing actions and EUP rollout will be country-specific, causing gradual impact rather than step-function; U.S. EUP clearance timing may delay full impact until end of 2027.
• Market Variables: Procedure growth impacted by ACA enrollment fluctuations, Medicaid eligibility changes, China tender competition/volumes, and capital placement cycles.
• Cost Pressures: Forecast includes higher input costs for freight and semiconductor memory.
• Regulatory Uncertainty: AI deployment and next-gen clearances (e.g., telesurgery 2028, GI robot) depend on regulatory confidence and approval timelines.
• Litigation: Final court approval for the $450M litigation settlement remains pending, though management views it as providing long-term certainty.

Management Tone on the Future:

• Confidence Level: High confidence in the long-term opportunity and durability of the business model; view pricing actions as a strategic reinvestment to broaden access and increase long-term value.
• Strategic Narrative: Emphasis on "durable U.S. procedure growth," expanding the "addressable market," and the "quintuple aim" (better outcomes, lower costs, increased access).
• Forward-Looking Hedges: Management notes that AI deployment and new indications (Cardiac, Breast) are early-stage and require evidence accumulation; ASC and new geography placements may be uneven quarter-to-quarter.

Miscellaneous:

• Share Count: Executed $2.9 billion in share repurchases in Q3 (avg price $377); reduced cash balance to $6.8 billion.
• Clinical Evidence: "Benign COMPARE" study published confirming da Vinci superiority over laparoscopy/open in high-volume benign procedures (lower conversion, fewer complications, shorter LOS); "Compare" study previously validated oncologic benefits.